porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2011333-35porozendo-4057Research ArticleСтатьиArticlesРОЛь цИТОКИНОВ В РАЗВИТИИ СЕРДЕЧНО-СОСУДИСТыХ ЗАБОЛЕВАНИЙ И ОСТЕОПОРОЗАROL' tsITOKINOV V RAZVITII SERDEChNO-SOSUDISTyKh ZABOLEVANIY I OSTEOPOROZAERShOVAO. B.

d.m.n., professor kafedry terapii IPDO YaGMA, zam.glavnogo vracha po lechebnoy rabote

-BELOVAK. Yu.

k.m.n., assistent kafedry terapii IPDO YaGMA, zav. gorodskim tsentrom osteoporoza

-NOVIKOVAI. V.

aspirant kafedry terapii IPDO YaGMA, vrach kardiologicheskogo otdeleniya OKB

-BARANOVA. A.

d.m.n., professor, prorektor po nauchnoy rabote

-NAZAROVAA. V.

aspirant kafedry terapii IPDO YaGMA, vrach gorodskogo tsentra osteoporoza

-ROMANOVAM. A.

aspirant kafedry terapii

-201115122011143№3 (2011)3335Copyright © ERShOVA O.B., BELOVA K.Y., NOVIKOVA I.V., BARANOV A.A., NAZAROVA A.V., ROMANOVA M.A., 20112011ERShOVA O.B., BELOVA K.Y., NOVIKOVA I.V., BARANOV A.A., NAZAROVA A.V., ROMANOVA M.A.ERShOVA O.B., BELOVA K.Y., NOVIKOVA I.V., BARANOV A.A., NAZAROVA A.V., ROMANOVA M.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4057

В последние годы активно изучается роль интерлейкинов в развитии ряда широко распространённых заболеваний, таких как патология сердечно-сосудистой системы (атеросклероз, артериальная гипертензия, ишемическая болезнь сердца и др.) и остеопороз. В обзоре приводятся данные проведённых исследований, посвящённых изучению значения цитокинов при возникновении данных заболеваний.

At thepresent time there is a great interest in médical researche devoted to investigation the role of cytokines (interleukins) in the pathogenesis of cardiovascular diseases (atherosclerosis, arterial hypertension, ischemic heart disease, etc.), and osteoporosis. The review provides data on the conducted research on the importance of cytokines in the event of these diseases.

интерлейкиныатеросклерозсердечно-сосудистые заболеванияостеопорозминеральная плотность костной тканиcytokinesinterleukinsatherosclerosiscardiovascular diseasesosteoporosisbone mineral densityReferencesCummings S.R., Nevitt M.C. Epidemiology of hip fractures and foils. In Kleerekoper M., Krane S.M. (eds). - Clinical disorders of bone and mineral Metabolism. Mary Ann Liebert Inc., Publishers, New York. - 1989. - p. 231-36.Cummings S.R., Nevitt M.C. Epidemiology of hip fractures and foils. In Kleerekoper M., Krane S.M. (eds). - Clinical disorders of bone and mineral Metabolism. Mary Ann Liebert Inc., Publishers, New York. - 1989. - p. 231-36.BarengoltsE.U., BermanM., KukrejaS.C., etal. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. — Calcif Tissue Int. - 1998. - № 62. -p. 209-13.BarengoltsE.U., BermanM., KukrejaS.C., etal. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. — Calcif Tissue Int. - 1998. - № 62. -p. 209-13.Jorgensen L., Joakimsen O., Berntsen R., et al. Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am J Epidemiol. - 2004. - V. 160. - № 6. - p. 549-53.Jorgensen L., Joakimsen O., Berntsen R., et al. Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am J Epidemiol. - 2004. - V. 160. - № 6. - p. 549-53.Kammerer СМ., Dualan A.A., Samollow P.B., et al. Bone mineral density, carotid artery intimal medial thickness, and the vitamin D receptor BsmI polymorphism in Mexican American women. - Calcif Tissue Int. - 2004. - V.75. -№4.-p. 292-8.Kammerer СМ., Dualan A.A., Samollow P.B., et al. Bone mineral density, carotid artery intimal medial thickness, and the vitamin D receptor BsmI polymorphism in Mexican American women. - Calcif Tissue Int. - 2004. - V.75. -№4.-p. 292-8.Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.Ridker PM. C-reactive protein, inflammation and cardiovascular disease — Clinical Update. Tex Heart Inst J. 2005; 32: 384-6. 9. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.Ridker PM. C-reactive protein, inflammation and cardiovascular disease — Clinical Update. Tex Heart Inst J. 2005; 32: 384-6. 9. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.Ramos AM, Pellanda LC, Gus I, Portal VL. Inflammatory markers of cardiovascular disease in the elderly. Arq Bras Cardiol.2009 Mar; 92(3):221-8, 227-34.Ramos AM, Pellanda LC, Gus I, Portal VL. Inflammatory markers of cardiovascular disease in the elderly. Arq Bras Cardiol.2009 Mar; 92(3):221-8, 227-34.Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin.Chem. 1997; 43 (1): 52-8.Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin.Chem. 1997; 43 (1): 52-8.Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993; 41 (2): 176-81.Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993; 41 (2): 176-81.Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990; 8: 253-78.Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990; 8: 253-78.Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, KuwabaraK, etal. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004; 35 (3): 677-81.Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, KuwabaraK, etal. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004; 35 (3): 677-81.Jenny NS, Tracy RP, Ogg MS, Luong LA, Kuller LH, Arnold AM, etal. In the elderly, interleukin-6 plasma levels and the — 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler'ThrombVasc Biol. 2002; 22: 2066-71.Jenny NS, Tracy RP, Ogg MS, Luong LA, Kuller LH, Arnold AM, etal. In the elderly, interleukin-6 plasma levels and the — 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler'ThrombVasc Biol. 2002; 22: 2066-71.Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, etal. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women.s Health and Aging Study. Circulation. 2001; 103: 947-53.Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, etal. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women.s Health and Aging Study. Circulation. 2001; 103: 947-53.Schomig K, Busch G, Steppich B, Sepp D, KaufmannJ , Stein A etal. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.Schomig K, Busch G, Steppich B, Sepp D, KaufmannJ , Stein A etal. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008;124:319-325.Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008;124:319-325.Panichi V, Taccola D, Rizza GM, Consani C, Ghiadoni L, Filippi C et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron ClinPract 2006;102:51-58.Panichi V, Taccola D, Rizza GM, Consani C, Ghiadoni L, Filippi C et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron ClinPract 2006;102:51-58.Kanda T, Hirao Y, Oshima S, Yuasa K, Taniguchi K, Nagai R et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996;77:304-307.Kanda T, Hirao Y, Oshima S, Yuasa K, Taniguchi K, Nagai R et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996;77:304-307.Romuk E, Skrzep-Poloczek B, Wojciechowska C, Tomasik A, Birkner E, Wodniecki J et al. Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest 2002;32:657-661.Romuk E, Skrzep-Poloczek B, Wojciechowska C, Tomasik A, Birkner E, Wodniecki J et al. Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest 2002;32:657-661.Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699-706.Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699-706.Abe Y, Kawakami M, Kuroki M, Yamamoto T, Fujii M, Kobayashi H et al. Transient rise in serum interleukin-8 concentration during acute myocardial infarction. Br Heart J 1993;70:132-134.Abe Y, Kawakami M, Kuroki M, Yamamoto T, Fujii M, Kobayashi H et al. Transient rise in serum interleukin-8 concentration during acute myocardial infarction. Br Heart J 1993;70:132-134.Schomig K, Busch G, Steppich B, Sepp D, Kaufmann J, Stein A et al. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.Schomig K, Busch G, Steppich B, Sepp D, Kaufmann J, Stein A et al. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 2006;30:1347-1355.Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 2006;30:1347-1355.von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation.Cytokine Growth Factor Rev. 2010 Dec;21(6):463-9. Epub 2010 Nov 12.von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation.Cytokine Growth Factor Rev. 2010 Dec;21(6):463-9. Epub 2010 Nov 12.Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J AtherosclerThromb 2001;8:30-32.Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J AtherosclerThromb 2001;8:30-32.Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Imunnol. 2004; 22: 929-79.Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Imunnol. 2004; 22: 929-79.Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons Ml, et al. Serum level of antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patient with acute coronary syndromes. Circulation. 2003; 107: 2109-14.Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons Ml, et al. Serum level of antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patient with acute coronary syndromes. Circulation. 2003; 107: 2109-14.Van Excel E, Gussekloo J, de Craen AJ, Bootsma- van der Wiel A, Frolich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002; 33: 1135-8.Van Excel E, Gussekloo J, de Craen AJ, Bootsma- van der Wiel A, Frolich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002; 33: 1135-8.=29Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart.Shock. 2008 Jul;30(1):3-10.=29Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart.Shock. 2008 Jul;30(1):3-10.=30Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.Nat ClinPractCardiovasc Med. 2009 Mar;6(3):192-9.=30Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.Nat ClinPractCardiovasc Med. 2009 Mar;6(3):192-9.==31Van H, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J ThrombHaemost. 2003; 1 (12): 2677-8.==31Van H, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J ThrombHaemost. 2003; 1 (12): 2677-8.=32Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66: 265-75.=32Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66: 265-75.=33Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108: 2317-22.=33Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108: 2317-22.=34Arron J, Choi Y. Bone versus immune sysem. Nature 2000;408:535-536.=34Arron J, Choi Y. Bone versus immune sysem. Nature 2000;408:535-536.=35Walsh MC, Kim N, Kadono Y, Rho J, et al. Osteoimmunology: Interplay Between the Immune system and Bone Metabolism. Annu. Rev. Immunol 2006;24:33-63.=35Walsh MC, Kim N, Kadono Y, Rho J, et al. Osteoimmunology: Interplay Between the Immune system and Bone Metabolism. Annu. Rev. Immunol 2006;24:33-63.=36Jorgensen NR. Cytokines and osteoporosis.Ugeskr Laeger.1997 Dec 29;160(1):24-8.=36Jorgensen NR. Cytokines and osteoporosis.Ugeskr Laeger.1997 Dec 29;160(1):24-8.=37Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.,Osteoporos Int. 2010 Aug;21(8):1287-93.=37Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.,Osteoporos Int. 2010 Aug;21(8):1287-93.=38 McLean R.R. Proinflammatorycytokinesandosteoporosis.,Cu rrOsteoporosRep. 2009 Dec;7(4):134-9.=38 McLean R.R. Proinflammatorycytokinesandosteoporosis.,Cu rrOsteoporosRep. 2009 Dec;7(4):134-9.=39 Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions.ntImmunol. 2010 Oct;22(10):805-16.=39 Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions.ntImmunol. 2010 Oct;22(10):805-16.=40Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. Interleukin-1 is essential for systemic inflammatory bone loss.Ann Rheum Dis. 2010 Jan;69(1):284-90.=40Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. Interleukin-1 is essential for systemic inflammatory bone loss.Ann Rheum Dis. 2010 Jan;69(1):284-90.=41Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protectiverole for IL-17receptorsignaling in ovariectomy-induced bone loss. Eur J Immunol. 2009 Oct;39(10):2831-9.=41Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protectiverole for IL-17receptorsignaling in ovariectomy-induced bone loss. Eur J Immunol. 2009 Oct;39(10):2831-9.Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/ osteoprotegerin balance. J Immunol 2003;170:2655-2662.Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/ osteoprotegerin balance. J Immunol 2003;170:2655-2662.Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.Karouzakis E, Neidhart M, Gay RE e, et al. Molecular and cellular basis of rheumatoid joint destruction. ImmunolLett 2006;106(1):8-13.Karouzakis E, Neidhart M, Gay RE e, et al. Molecular and cellular basis of rheumatoid joint destruction. ImmunolLett 2006;106(1):8-13.Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts.Gut. 2008 May;57(5):684-94.Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts.Gut. 2008 May;57(5):684-94.Riggs B. The mechanisms of estrogen regulation of bone resorption. J ClinInvestig 2000;106:1203- 1204.Riggs B. The mechanisms of estrogen regulation of bone resorption. J ClinInvestig 2000;106:1203- 1204.Pfeilschifter J, Köditz R, Pfohl M, et al. Changes in Proinflammatory Cytokine Activity after Menopause. Endocrine Reviews 2002;23:90-119.Pfeilschifter J, Köditz R, Pfohl M, et al. Changes in Proinflammatory Cytokine Activity after Menopause. Endocrine Reviews 2002;23:90-119.Gertz ER, Silverman NE, Wise KS, Hanson KB, Alekel DL, Stewart JW, Perry CD, Bhupathiraju SN, Kohut ML, Van Loan MD. J ClinDensitom.Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation. 2010 Jul-Sep;13(3):277-82.Gertz ER, Silverman NE, Wise KS, Hanson KB, Alekel DL, Stewart JW, Perry CD, Bhupathiraju SN, Kohut ML, Van Loan MD. J ClinDensitom.Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation. 2010 Jul-Sep;13(3):277-82.Sun T, Wang X, Liu Z, Chen X, Zhang J. Epub 2011 Feb 23. Plasma concentrations of pro- and anti-inflammatory cytokines and outcome prediction in elderly hip fracture patients.Injury. 2011 Jul;42(7):707-13.Sun T, Wang X, Liu Z, Chen X, Zhang J. Epub 2011 Feb 23. Plasma concentrations of pro- and anti-inflammatory cytokines and outcome prediction in elderly hip fracture patients.Injury. 2011 Jul;42(7):707-13.

The authors declare that there are no conflicts of interest present.